Bayer Reports P-III (PEACE-3) Trial Data on Xofigo Combination for Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases

Why It Matters

The OS gain positions the Xofigo‑enzalutamide regimen as a potential new standard for asymptomatic or mildly symptomatic mCRPC patients, expanding radium‑223’s use beyond purely symptomatic settings. This could reshape treatment sequencing and boost Bayer’s oncology portfolio.

Key Takeaways

• Xofigo + enzalutamide cut death risk 24%
• Median overall survival extended to 38.2 months
• Radiographic PFS improved to 19.4 months
• Trial enrolled asymptomatic/mildly symptomatic mCRPC patients
• Results to be presented at ASCO GU 2026

Pulse Analysis

Radium‑223 dichloride, marketed as Xofigo, has been a cornerstone for bone‑dominant metastatic prostate cancer since its ALSYMPCA trial showed survival and skeletal event benefits in symptomatic patients. By pairing it with enzalutamide, a potent androgen‑receptor inhibitor, Bayer aimed to address a broader patient segment—those who are asymptomatic or only mildly symptomatic—where treatment options have been limited. The PEACE‑3 trial enrolled men with at least two bone lesions and low pain scores, delivering a rigorous head‑to‑head comparison against enzalutamide monotherapy.

The data revealed a median overall survival of 38.2 months for the combination versus 32.6 months for enzalutamide alone, translating into a 24% relative reduction in mortality. Radiographic progression‑free survival also improved, reaching 19.4 months compared with 16.4 months. These outcomes not only confirm the additive efficacy of radium‑223 in a less symptomatic cohort but also suggest a synergistic mechanism where androgen blockade may enhance radionuclide uptake in bone lesions. The statistical robustness of the findings, slated for presentation at ASCO GU 2026 and publication in the Annals of Oncology, underscores their clinical relevance.

For clinicians, the PEACE‑3 results provide a compelling argument to consider Xofigo plus enzalutamide earlier in the treatment algorithm, potentially delaying the need for chemotherapy or newer hormonal agents. From a market perspective, Bayer stands to strengthen its oncology pipeline and capture a larger share of the mCRPC space. Ongoing follow‑up will be critical to assess long‑term safety, quality‑of‑life outcomes, and real‑world adoption, but the trial sets a new benchmark for combination strategies targeting bone‑predominant prostate cancer.